Hims & Hers rises after plan to sell Eli Lilly's weight loss drug on its platform

Shares of telehealth firm Hims & Hers HIMS.N rise 11.2% to $32.88

HIMS says it plans to sell Eli Lilly's LLY.N weight-loss and diabetes drug on its platform

Co says it will offer both branded versions of Lilly's tirzepatide, the active ingredient in weight loss drug Zepbound and diabetes medicine Mounjaro, as well as generics of Novo Nordisk's NOVOb.CO diabetes drug, liraglutide

HIMS joins its peers such as Teladoc TDOC.N and LifeMD LFMD.O to offer Lilly's Zepbound ahead of restrictions on selling copies known as compounded drugs

Including session's moves, HIMS stock up 36.4% YTD